---

$3.46

+0.1950 ( +5.98% ) 43.9K

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-01-23	Sale	-43250.00	Newman Michael James
2024-01-23	Sale	-40000.00	Sassi Nir
2023-08-16	Buy	44354.00	Anderson Glen R.
2023-08-07	Sale	-90000.00	Waltzman Roger J.